MedTrace Logo

High GRP78 Levels in Covid-19 Infection: A Case-Control Study

NCT04628637 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 144

Last updated 2020-11-13

No results posted yet for this study

Summary

Covid-19 infection was declared a global pandemic by WHO on March 11, 2020. GRP78 protein is known to be involved in the intrusion of numerous viruses. Our current study tries to provide some insight into the variation of GRP78 protein levels in patients with Covid-19(-) pneumonia, Covid-19(+) pneumonia, and CT negative Covid-19 infection in comparison to the normal population through a larger number of cases.

42 patients who have Covid-19(-) pneumonia; 72 patients who have Covid-19 infection (30 pneumonia,42 CT negative patients) and 30 patient who have no known diseases (control group) will be included in the study after the clinical and radiological evaluation. Serum GRP78 levels of the subjects will be measured through a commercially available enzyme-linked immunosorbent assay (ELISA) kit.

Conditions

  • Covid19
  • Endoplasmic Reticulum Stress

Interventions

OTHER

Serum protein level analysis

Serum GRP78 levels of the subjects were measured through a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Human Glucose Regulated Protein 78 (GRP78) ELISA Kit, Sun Long, SL2048Hu, China), as per the manufacturer's protocol. The detection rate of this kit is 16 pg/mL.

Sponsors & Collaborators

  • Pamukkale University Faculty of Medicine

    collaborator UNKNOWN

  • Acibadem Mehmet Ali Aydinlar University Faculty of Medicine

    collaborator UNKNOWN

  • Kafkas University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-16
Primary Completion
2020-10-01
Completion
2020-10-10

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04628637 on ClinicalTrials.gov